Quick Links
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
近日，安斯泰来中国凭借2022年在公益事业方面的突出表现，再次斩获多个公益奖项。凭借“改变明天”的公益项目，安斯泰来已经连续两年上榜“CSRC...
-该组合有可能成为在这种治疗场景中结合抗体药物偶联物和免疫疗法的首个治疗选择-...
安斯泰来GLOW临床试验，即CLDN18.2阳性、HER2阴性的局部晚期不可切除或转移性胃癌和胃食管交界处癌的第二项III期试验，达到了无进展生存期（PFS）的
*本文来源于近期E药经理人对安斯泰来大中华区总经理滨口洋先生及其团队的专访，全文如下：...
安斯泰来SPOTLIGHT临床试验达到无进展生存期（PFS）的主要终点 详细数据将于未来召开的的学术会议上公布...
Follow China news
